ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 23 Issue : 2
Current Issue Archive Popular Article Ahead of Print

   
Quick Search





 
Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification [Anatol J Cardiol]
Anatol J Cardiol. 2020; 23(2): 70-78 | DOI: 10.14744/AnatolJCardiol.2019.89916  

Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification

Alberto Aimo, Raffaele De Caterina
Department of Cardiology, University Hospital of Pisa; Pisa-Italy

The need for aspirin therapy as part of primary prevention of cardiovascular (CV) disease is currently being highly debated, especially after 3 studies in different settings reported that a reduction in ischemic events is largely counterbalanced by an increase in bleeding events. One possible explanation for these results is the progressive reduction in the risk of major adverse cardiovascular events (MACE) as a result of primary prevention, which has accompanied global education programs that have led to patients smoking less, exercising more, and increasingly undertaking lipid-lowering therapies. Based on a meta-regression of the benefits and harmful effects of aspirin therapy in primary prevention as a function of the 10-year risk of MACE, we favor a differentiated and personalized approach that acknowledged differences between patients and emphasized an individualized assessment of benefits and risks. Following general preventive measures (physical exercise, cessation of smoking, treatment of hypertension and hypercholesterolemia, etc.), an individualized approach to prescribing aspirin is still warranted. When patients are less than 70 years of age, clinicians should assess the 10-year CV risk. Aspirin treatment should be considered only when the CV risk is very high and the bleeding risk is low, after taking into account the patientís preferences.

Keywords: aspirin, primary cardiovascular prevention, bleeding, major acute cardiovascular events, MACE, benefit-risk balance


Alberto Aimo, Raffaele De Caterina. Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification. Anatol J Cardiol. 2020; 23(2): 70-78

Corresponding Author: Raffaele De Caterina, Italy


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2018 Turkish Society of Cardiology